治疗肾性贫血新药:vadadustat

A new drug in treatment of renal anemia: vadadustat

慢性肾脏病(CKD)是一种长期进展性疾病,贫血是晚期CKD的主要症状之一。红细胞生成刺激剂(ESA)是目前治疗肾性贫血的主导药物,然而该类药物潜在的心血管安全风险限制了ESA的应用。低氧诱导因子-脯氨酰羟化酶抑制剂(HIF-PHI)可通过多种作用促进红细胞生成,有效纠正贫血。vadadustat是由Akebia Therapeutics公司研发的口服HIF-PHI,于2020年6月29日在日本获批上市,用于治疗患有CKD引起贫血的成年患者。临床试验表明,vadadustat对CKD透析和非透析贫血患者疗效显著,不良反应少。

Chronic kidney disease(CKD) is a long-term progressive disease. Anemia is one of the typical symptoms of advanced CKD. Erythropoiesis stimulating agents(ESA) are the mainstay of renal anemia management but cardiovascular safety concerns have limited their use. Hypoxia-inducible factor prolyl hydroxylase inhibitors(HIF-PHI) can promote erythrocytogeny through various actions and correct anemia effectively. Vadadustat, an oral HIF-PHI developed by Akebia Therapeutics Inc., was approved in Japan for the treatment of adult patients with CKD-associated anemia on June 29, 2020.Clinical trials have shown that vadadustat is effectively in treating CKD-associated anemia of non-dialysis or dialysis patients with few adverse reactions.